| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 30/05/2024 | 23:55 | GlobeNewswire Inc. | QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications | NASDAQ:MYGN | Myriad Genetics Inc |
| 24/05/2024 | 00:00 | GlobeNewswire Inc. | Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting | NASDAQ:MYGN | Myriad Genetics Inc |
| 16/05/2024 | 22:05 | GlobeNewswire Inc. | New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer | NASDAQ:MYGN | Myriad Genetics Inc |
| 15/05/2024 | 23:49 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:MYGN | Myriad Genetics Inc |
| 15/05/2024 | 22:24 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:MYGN | Myriad Genetics Inc |
| 08/05/2024 | 14:23 | IH Market News | Reddit Rises 15% After First Quarterly Report, Upstart and Twilio Plunge Due to Weak Q2 Forecast, and More in Earnings | NASDAQ:MYGN | Myriad Genetics Inc |
| 08/05/2024 | 14:14 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:MYGN | Myriad Genetics Inc |
| 07/05/2024 | 22:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MYGN | Myriad Genetics Inc |
| 07/05/2024 | 22:05 | GlobeNewswire Inc. | Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA | NASDAQ:MYGN | Myriad Genetics Inc |
| 07/05/2024 | 15:00 | GlobeNewswire Inc. | Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business | NASDAQ:MYGN | Myriad Genetics Inc |
| 30/04/2024 | 22:05 | GlobeNewswire Inc. | Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024 | NASDAQ:MYGN | Myriad Genetics Inc |
| 17/04/2024 | 14:00 | GlobeNewswire Inc. | Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor | NASDAQ:MYGN | Myriad Genetics Inc |
| 16/04/2024 | 15:15 | GlobeNewswire Inc. | New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen | NASDAQ:MYGN | Myriad Genetics Inc |
| 09/04/2024 | 14:00 | GlobeNewswire Inc. | Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing | NASDAQ:MYGN | Myriad Genetics Inc |
| 22/03/2024 | 02:40 | GlobeNewswire Inc. | Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date | NASDAQ:MYGN | Myriad Genetics Inc |
| 20/03/2024 | 21:05 | GlobeNewswire Inc. | Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device | NASDAQ:MYGN | Myriad Genetics Inc |
| 28/02/2024 | 14:31 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:MYGN | Myriad Genetics Inc |
| 27/02/2024 | 22:05 | GlobeNewswire Inc. | Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fo | NASDAQ:MYGN | Myriad Genetics Inc |
| 27/02/2024 | 15:15 | GlobeNewswire Inc. | Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3 | NASDAQ:MYGN | Myriad Genetics Inc |
| 21/02/2024 | 22:05 | GlobeNewswire Inc. | Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 | NASDAQ:MYGN | Myriad Genetics Inc |
| 15/02/2024 | 22:05 | GlobeNewswire Inc. | Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health | NASDAQ:MYGN | Myriad Genetics Inc |
| 14/02/2024 | 22:47 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:MYGN | Myriad Genetics Inc |
| 01/02/2024 | 15:25 | GlobeNewswire Inc. | Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics | NASDAQ:MYGN | Myriad Genetics Inc |
| 30/01/2024 | 23:00 | GlobeNewswire Inc. | Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology | NASDAQ:MYGN | Myriad Genetics Inc |
| 29/01/2024 | 22:21 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:MYGN | Myriad Genetics Inc |
| 19/01/2024 | 00:10 | GlobeNewswire Inc. | Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics | NASDAQ:MYGN | Myriad Genetics Inc |
| 09/01/2024 | 22:05 | GlobeNewswire Inc. | Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO | NASDAQ:MYGN | Myriad Genetics Inc |
| 03/01/2024 | 22:05 | GlobeNewswire Inc. | Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:MYGN | Myriad Genetics Inc |
| 21/12/2023 | 14:30 | GlobeNewswire Inc. | Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance | NASDAQ:MYGN | Myriad Genetics Inc |
| 20/12/2023 | 14:00 | GlobeNewswire Inc. | Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care | NASDAQ:MYGN | Myriad Genetics Inc |